Network pharmacology and experimental validation reveal that betulin alleviates 5-fluorouracil-induced intestinal injury by inhibiting intestinal senescence and enhances antitumor efficacy.
{"title":"Network pharmacology and experimental validation reveal that betulin alleviates 5-fluorouracil-induced intestinal injury by inhibiting intestinal senescence and enhances antitumor efficacy.","authors":"Zhi-Wei Wang, Xiao-Jian Wu, Qian-Long Dai, Zhen-Lin Liu, Cheng-Gang Zhao, Wei Lian, Yue Zhao, Li-Hua Li, Xiao-Bo Wang","doi":"10.1016/j.jpet.2025.103666","DOIUrl":null,"url":null,"abstract":"<p><p>5-Fluorouracil (5-FU) remains the first-line chemotherapeutic agent for colorectal cancer. Although 5-FU significantly improves patient survival, its severe gastrointestinal toxicity-particularly intestinal injury and diarrhea-impairs treatment adherence and patient quality of life, often leading to therapeutic failure. Thus, effective interventions to prevent or mitigate these adverse effects are urgently needed. Betulin (BET), a natural pentacyclic triterpenoid derived primarily from birch bark, exhibits various biological activities, including anti-inflammatory, antioxidant, antiviral, and antitumor effects. Its anti-inflammatory and antioxidant properties suggest betulin (BET) as a promising candidate for alleviating chemotherapy-induced tissue damage. However, its impact on 5-FU-induced intestinal injury remains unclear. The findings of this study revealed that 5-FU led to significant intestinal injury by promoting cellular senescence and exacerbating the inflammatory response. BET mitigates these effects by decreasing senescence-associated β-galactosidase activity and downregulating key senescence markers such as p53, p21, and p16. Moreover, BET modulates senescence-associated secretory phenotype factors, thereby reversing the proinflammatory microenvironment elicited by 5-FU. Integrating network pharmacology, Mendelian randomization, and experimental validation, we identified the mechanistic target of rapamycin/mitogen-activated protein kinase signaling pathway as a pivotal mediator of BET's protective effects against 5-FU-induced intestinal injury. In conclusion, our study reveals that 5-FU-induced intestinal damage is driven by cellular senescence, which BET effectively ameliorates through suppression of senescence and inflammation. These findings provide a novel framework for targeting antisenescence strategies to alleviate chemotherapy-associated intestinal toxicity. SIGNIFICANCE STATEMENT: This study identifies betulin as a novel agent that alleviates 5-fluorouracil-induced intestinal injury by inhibiting cellular senescence and inflammation via the mechanistic target of rapamycin/mitogen-activated protein kinase pathways. These findings highlight antisenescence as a promising therapeutic strategy to mitigate chemotherapy-induced gastrointestinal toxicity.</p>","PeriodicalId":16798,"journal":{"name":"Journal of Pharmacology and Experimental Therapeutics","volume":"392 9","pages":"103666"},"PeriodicalIF":3.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacology and Experimental Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jpet.2025.103666","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
5-Fluorouracil (5-FU) remains the first-line chemotherapeutic agent for colorectal cancer. Although 5-FU significantly improves patient survival, its severe gastrointestinal toxicity-particularly intestinal injury and diarrhea-impairs treatment adherence and patient quality of life, often leading to therapeutic failure. Thus, effective interventions to prevent or mitigate these adverse effects are urgently needed. Betulin (BET), a natural pentacyclic triterpenoid derived primarily from birch bark, exhibits various biological activities, including anti-inflammatory, antioxidant, antiviral, and antitumor effects. Its anti-inflammatory and antioxidant properties suggest betulin (BET) as a promising candidate for alleviating chemotherapy-induced tissue damage. However, its impact on 5-FU-induced intestinal injury remains unclear. The findings of this study revealed that 5-FU led to significant intestinal injury by promoting cellular senescence and exacerbating the inflammatory response. BET mitigates these effects by decreasing senescence-associated β-galactosidase activity and downregulating key senescence markers such as p53, p21, and p16. Moreover, BET modulates senescence-associated secretory phenotype factors, thereby reversing the proinflammatory microenvironment elicited by 5-FU. Integrating network pharmacology, Mendelian randomization, and experimental validation, we identified the mechanistic target of rapamycin/mitogen-activated protein kinase signaling pathway as a pivotal mediator of BET's protective effects against 5-FU-induced intestinal injury. In conclusion, our study reveals that 5-FU-induced intestinal damage is driven by cellular senescence, which BET effectively ameliorates through suppression of senescence and inflammation. These findings provide a novel framework for targeting antisenescence strategies to alleviate chemotherapy-associated intestinal toxicity. SIGNIFICANCE STATEMENT: This study identifies betulin as a novel agent that alleviates 5-fluorouracil-induced intestinal injury by inhibiting cellular senescence and inflammation via the mechanistic target of rapamycin/mitogen-activated protein kinase pathways. These findings highlight antisenescence as a promising therapeutic strategy to mitigate chemotherapy-induced gastrointestinal toxicity.
期刊介绍:
A leading research journal in the field of pharmacology published since 1909, JPET provides broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology.